FENM4PTSD
Financiado
Development of a novel class of therapeutics for PTSD treatment and other neurod...
Development of a novel class of therapeutics for PTSD treatment and other neurodegenerative disorders
ReST Therapeutics is a French biotech company founded late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms f...
ReST Therapeutics is a French biotech company founded late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms followed by Alzheimer Disease (AD).
Our lead candidate - FENM is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs. FENM will enter First-in-Human in June 2023 to initiate the clinical demonstration on PTSD.
ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders. With the EIC support, ReST will bring FENM to clinical PoC (PhIIb) by 2027, secure a partnership with a pharma company and develop new small molecules to expand its pipeline.
ver más
Duración del proyecto: 28 meses
Fecha Inicio: 2023-12-08
Fecha Fin: 2026-04-30
Fecha Fin: 2026-04-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-08
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
REST THERAPEUTICS
No se ha especificado una descripción o un objeto social para esta compañía.
